Navigation Links
Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Date:7/18/2012

CAMBRIDGE, England, July 18, 2012 /PRNewswire/ --

Phase I study data indicates CNV2197944's optimal profile for a chronic pain medication

Convergence Pharmaceuticals Limited ("Convergence"), the company focused on the development of novel and high value analgesic medicines for the treatment of chronic pain, today announces that it is designing Phase II proof of concept studies with CNV2197944 in neuropathic pain, following successful completion of Phase I. This novel, small molecule, state-dependent calcium channel blocker, is designed to selectively inhibit highly active Cav2.2 channels. It is the only truly selective Cav2.2 blocker in clinical development and has the potential to be a first in class treatment for chronic pain. Convergence is conducting the development of CNV2197944 on behalf of Calchan Ltd.

Results of the Phase I, placebo-controlled, multiple ascending dose clinical study with orally administered CNV2197944, demonstrated that the drug was well tolerated in all subjects, with few adverse events reported at doses that are expected to fall within the predicted therapeutic range. The compound was also well absorbed following oral administration, with a pharmacokinetic profile that is predictable and consistent in both young and elderly subjects.  These characteristics indicate CNV2197944's optimal profile for a chronic pain medication.

In view of these favourable data, well powered Phase II proof of concept trials for CNV2197944 in neuropathic pain are now being planned.

CNV2197944 - a first in class molecule with potential to be a first in class treatment

CNV2197944 is a novel, small molecule, state-dependent calcium channel blocker, designed to selectively inhibit highly active Cav2.2 channels. Preclinical studies demonstrated that CNV2197944 could have analgesic potential for a broad range of chronic pain conditions. Extensive safety and toxicology studies to support the clinical development of CNV2
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. The Convergence of Art, Science and Beer
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
6. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
7. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
8. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
9. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
10. Questcor Pharmaceuticals Expands Repurchase Program
11. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... The new Public-Private Partnership (PPP) in Photonics established ... annual meeting drew praise from community leaders from SPIE ... the action “a huge step forward … a lasting ... , The Board of Stakeholders voted to approve in ... its 29 April meeting in Brussels, which was sponsored ...
(Date:5/17/2013)... , May 17, 2013  Cellular Biomedicine Group ... 50% enrollment of the total projected enrollment required ... safety and preliminary efficacy of the medical technology ... Knee Osteoarthritis (KOA). To date the trial has ... The Phase I open label clinical research ...
(Date:5/17/2013)... Health, Inc., a company developing natural compounds to address ... is today reporting top-line results from a Phase Ib ... drug-resistant epilepsy.  The data are being presented at the ... Dr. Steven Schachter , Harvard Medical ... In this study, INS001 appeared safe and well tolerated. ...
(Date:5/17/2013)... Frederick, MD (PRWEB) May 17, 2013 ... release of ezColony version 4.1, a versatile refinement ... world-class premier software solution, improves its advanced methodical ... animal facilities with ezColony 4.1. The network-based platform ... to conduct effective research. While continuing to emphasize ...
Breaking Biology Technology:SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 2SPIE Joins in Praise for ‘Huge Step Forward’ for Innovation R&D Enabled by Photonics21 Actions 3Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis 2Insero Health Reports Positive Data on Phase I Trial of Novel Therapy for Drug-resistant Epilepsy 2RURO Introduces ezColony 4.1 – The Versatile Transgenic Animal Colony Management Software 2
... COPENHAGEN, Denmark and LELYSTAD, Netherlands, March 3, Genmab ... of a research collaboration aimed at identifying fully,human ... those that are difficult to address using,commonly available ... antibodies. These difficulties can for example be due ...
... Pathology LIS Interface to Digital Pathology Information ... ... 3 IMPAC Medical,Systems, Inc. (IMPAC), an Elekta company and ... Aperio Technologies, (Aperio) a global leader in digital pathology for,the ...
... LONDON, March 3 Amarin Corporation plc,(NASDAQ: ... has signed an exclusive license with,Scarista Limited ... a broad intellectual property portfolio in the ... is complementary to Amarin,s,existing lipid-based development programs ...
Cached Biology Technology:Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 2Genmab and Pepscan to Identify Human Antibodies Against Intractable Targets 3IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology 2IMPAC Medical Systems and Aperio to Develop Integrated Solution for Anatomic Pathology 3Amarin Secures Global Intellectual Property Rights for Lipid Programs 2Amarin Secures Global Intellectual Property Rights for Lipid Programs 3Amarin Secures Global Intellectual Property Rights for Lipid Programs 4
(Date:5/18/2013)... increasing number of U.S. children are experiencing gastrointestinal ... research presented at Digestive Disease Week (DDW). ... the Cleveland Clinic Children,s Hospital found that obese ... compared to their lean counterparts. The pattern showed ... be correlated to potential complications associated with obesity, ...
(Date:5/17/2013)... will celebrate the science and technology of the ... during the inaugural Atlanta Science Festival, March 22-29, ... museums, corporations, K-12 schools and universities, the festival ... children and adults at venues across the city. ... The annual Atlanta Science Festival is a collaboration ...
(Date:5/17/2013)... human-caused climate change may have little impact on ... of recent studies that predict their widespread extinction ... which appear in the journal Global Change ... a creature thought to be doomed: http://onlinelibrary.wiley.com/doi/10.1111/gcb.12253/abstract ... especially forest lizards, will be hard hit by ...
Breaking Biology News(10 mins):New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3First Atlanta Science Festival set for 2014 2Climate change may have little impact on tropical lizards 2
... China -- The study on single-nucleotide resolution structural variations (SVs) ... Nature Biotechnology . This study was performed ... largest genomics organization in the world, and demonstrates that whole ... for developing a more comprehensive SV map of individuals. ...
... A genome-wide association study published in the August issue ... genetic variations that can predict which patients with Hodgkin,s ... years after treatment. Knowing in advance who is at ... risks for patients who are most susceptible to long-term ...
... have produced one of the first high-resolution genetic maps ... precise locations across the genome where DNA from a ... a biological process called "recombination." This process results in ... the person,s children. The new map ...
Cached Biology News:BGI develops new strategy to uncover structural variations of human genomes 2BGI develops new strategy to uncover structural variations of human genomes 32 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma 22 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma 3Life scientists use novel technique to produce genetic map for African Americans 2Life scientists use novel technique to produce genetic map for African Americans 3Life scientists use novel technique to produce genetic map for African Americans 4
Recombinant Mouse Serpin A1/alpha-1-Antitrypsin, CF Protein Family: Coagulation, Serine Protease Regulators...
... hydrophobic plastic supports that retain stiffness in ... solutions. Paper segments on each strip have ... Complementary indicator charts provide clear comparison. Full-range ... units; In packs of 100; each strip ...
X-prolyl aminopeptidase (aminopeptidase P) 1, soluble...
This kit only detects beta-galactosidase activity at pH 6 in cultured cells andtissue sections. Beta-galactosidase activity at pH 6 ispresent only in senescent cells, and is not found inpresenescent...
Biology Products: